Skip to main content

Healthy Male Volunteers

14
Pipeline Programs
16
Companies
50
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 23 programs with unclassified modality

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Hanlim Pharm
Hanlim PharmKorea - Seoul
4 programs
4
CelecoxibPhase 1Small Molecule1 trial
HL237 tabletPhase 11 trial
Livasupril Cap.160/2mgPhase 11 trial
micronized fenofibrate 160mgPhase 11 trial
Active Trials
NCT01549743Completed30Est. Jun 2012
NCT04633733Unknown24Est. Jan 2021
NCT02250976Completed41Est. Oct 2014
+1 more trials
Chong Kun Dang Pharmaceutical
3 programs
3
MetforminPhase 11 trial
S-amlodipine 5mg,Telmisartan 80mgPhase 11 trial
Telmisartan 80mg, S-amlodipine 5mgPhase 11 trial
Active Trials
NCT01005160Completed24Est. Feb 2010
NCT01356043Completed24Est. Aug 2011
NCT01356017Completed32Est. Sep 2011
Pfizer
PfizerNEW YORK, NY
2 programs
2
NXL104Phase 12 trials
[14C] PF-07976016Phase 11 trial
Active Trials
NCT01448395Completed6Est. Nov 2011
NCT01290900Completed54Est. May 2011
NCT07015918Completed8Est. Aug 2025
Prevail Therapeutics
1 program
1
DrugPhase 11 trial
Active Trials
NCT01577355Completed8Est. Jun 2012
Hanmi Pharmaceutical
1 program
1
HGP1607Phase 11 trial
Active Trials
NCT03089112Completed30Est. Jun 2017
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
IV methylnaltrexonePhase 11 trial
Active Trials
NCT01367483Completed6Est. Jun 2005
Orion
OrionUK - Cambridge
1 program
1
ORM-12741Phase 1
Orion Pharma
Orion PharmaUK - Reading
1 program
1
ORM-12741Phase 11 trial
Active Trials
NCT00817544Completed6Est. Mar 2009
UCB Pharma
UCB PharmaBelgium - Brussels
3 programs
LacosamideN/A1 trial
LacosamidePHASE_11 trial
UCB0107PHASE_11 trial
Active Trials
NCT01382017Completed18Est. Aug 2012
NCT03086382Completed24Est. Mar 2017
NCT03464227Completed52Est. Dec 2018
Bristol Myers Squibb
2 programs
BMS-986165PHASE_15 trials
[14C]-BMS-986196PHASE_11 trial
Active Trials
NCT06875960Recruiting35Est. Dec 2026
NCT06979453Recruiting366Est. Aug 2034
NCT06869551Recruiting60Est. Mar 2031
+3 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
DrugPHASE_1
Eisai
EisaiChina - Liaoning
1 program
E6011PHASE_11 trial
Active Trials
NCT01731275Completed64Est. Aug 2013
Opko Health
Opko HealthMIAMI, FL
1 program
SomatrogonPHASE_11 trial
Active Trials
NCT03810664Completed49Est. Apr 2019
Xenon Pharmaceuticals
1 program
XPF-008PHASE_11 trial
Active Trials
NCT03468725Completed20Est. Jul 2018
PMV Pharma
PMV PharmaPRINCETON, NJ
1 program
[14C]-PC14586PHASE_11 trial
Active Trials
NCT05523687CompletedEst. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165
Pfizer[14C] PF-07976016
Bristol Myers SquibbBMS-986165
Bristol Myers SquibbBMS-986165

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 4,595 patients across 50 trials

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Start: Feb 2026Est. completion: Dec 202635 patients
Phase 4Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Start: Dec 2025Est. completion: Aug 2034366 patients
Phase 3Recruiting

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Start: Mar 2025Est. completion: Mar 203160 patients
Phase 3Recruiting

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Start: Nov 2019Est. completion: Jan 2022220 patients
Phase 3Completed

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Start: Aug 2019Est. completion: Jul 20261,466 patients
Phase 3Active Not Recruiting

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Start: Apr 2019Est. completion: Mar 202174 patients
Phase 3Completed

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Start: Mar 2021Est. completion: Nov 202338 patients
Phase 2Completed

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Start: Jul 2019Est. completion: Sep 202116 patients
Phase 2Terminated

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Start: Jul 2019Est. completion: Apr 2023131 patients
Phase 2Completed

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Start: Jul 2018Est. completion: Oct 2023239 patients
Phase 2Terminated

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Start: Sep 2017Est. completion: Oct 2021363 patients
Phase 2Completed

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Start: Nov 2016Est. completion: Nov 2017268 patients
Phase 2Completed
NCT07015918Pfizer[14C] PF-07976016

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men

Start: Jun 2025Est. completion: Aug 20258 patients
Phase 1Completed

A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

Start: Jan 2025Est. completion: Apr 202526 patients
Phase 1Completed

Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

Start: Oct 2024Est. completion: Jun 202552 patients
Phase 1Completed

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Start: Aug 2023Est. completion: Oct 20238 patients
Phase 1Completed

AME Study of [14C]-PC14586 in Healthy Male Participants

Start: Sep 2022Est. completion: Nov 2022
Phase 1Completed

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

Start: Aug 2020Est. completion: Nov 202040 patients
Phase 1Completed

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

Start: Aug 2020Est. completion: Jan 202124 patients
Phase 1Unknown

Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

Start: Feb 2020Est. completion: Mar 202018 patients
Phase 1Completed

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Start: Dec 2019Est. completion: Feb 202018 patients
Phase 1Completed

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Start: Oct 2019Est. completion: Nov 201948 patients
Phase 1Completed

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Start: Sep 2019Est. completion: Oct 201916 patients
Phase 1Completed

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Start: Aug 2019Est. completion: Dec 201933 patients
Phase 1Completed

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Start: Aug 2019Est. completion: Sep 201916 patients
Phase 1Completed

A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

Start: May 2019Est. completion: Jul 201921 patients
Phase 1Completed

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

Start: May 2019Est. completion: May 201916 patients
Phase 1Completed

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

Start: Apr 2019Est. completion: Feb 202044 patients
Phase 1Completed

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Start: Jan 2019Est. completion: May 20199 patients
Phase 1Completed

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Start: Jan 2019Est. completion: Apr 201949 patients
Phase 1Completed

A Taste Assessment of BMS-986165 in Healthy Participants

Start: Oct 2018Est. completion: Nov 20189 patients
Phase 1Completed

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

Start: Aug 2018Est. completion: Oct 2018131 patients
Phase 1Completed

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Start: May 2018Est. completion: Sep 201884 patients
Phase 1Completed

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Start: Mar 2018Est. completion: May 201854 patients
Phase 1Completed

A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects

Start: Feb 2018Est. completion: Dec 201852 patients
Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Start: Feb 2018Est. completion: Jul 201820 patients
Phase 1Completed

A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation

Start: Sep 2017Est. completion: Nov 201749 patients
Phase 1Completed

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

Start: Sep 2017Est. completion: Dec 201749 patients
Phase 1Completed

Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501

Start: Mar 2017Est. completion: Jun 201730 patients
Phase 1Completed

A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects

Start: Feb 2017Est. completion: Mar 201724 patients
Phase 1Completed

Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin

Start: Feb 2017Est. completion: Mar 201720 patients
Phase 1Completed

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

Start: Jan 2017Est. completion: Feb 20176 patients
Phase 1Completed

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Start: Oct 2015Est. completion: Nov 2016140 patients
Phase 1Completed
NCT02250976Hanlim PharmLivasupril Cap.160/2mg

The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca

Start: Sep 2014Est. completion: Oct 201441 patients
Phase 1Completed
NCT01767610Hanlim Pharmmicronized fenofibrate 160mg

Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin

Start: Jan 2013Est. completion: Jul 201324 patients
Phase 1Completed

A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)

Start: Aug 2012Est. completion: Aug 201364 patients
Phase 1Completed

The Pharmacokinetic Interaction Between Celecoxib and Rebamipide

Start: May 2012Est. completion: Jun 201230 patients
Phase 1Completed

A Study of LY2784544 in Healthy Male Subjects

Start: Apr 2012Est. completion: Jun 20128 patients
Phase 1Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104

Start: Oct 2011Est. completion: Nov 20116 patients
Phase 1Completed
NCT01356017Chong Kun Dang PharmaceuticalTelmisartan 80mg, S-amlodipine 5mg

CKD-828 Drug Interaction Study (Telmisartan)

Start: Jun 2011Est. completion: Sep 201132 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 4,595 patients
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.